Sign up to save your podcasts
Or
Share What To Expect After China’s First siRNA Firm Went Public
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
What To Expect After China’s First siRNA Firm Went Public
In this episode of the China biopharma English-language podcast, Xu Hu talks about the siRNA area, including possible industry and R&D environment changes for Chinese firms developing these therapies and trends in deals of China-originated siRNA assets this year.
Story link: Chinese siRNA Contenders Set For Transitions, Deals In 2026
View all episodes
By Norstella
4.1
2828 ratings
In this episode of the China biopharma English-language podcast, Xu Hu talks about the siRNA area, including possible industry and R&D environment changes for Chinese firms developing these therapies and trends in deals of China-originated siRNA assets this year.
Story link: Chinese siRNA Contenders Set For Transitions, Deals In 2026
More shows like Citeline Podcasts
View all
Marketplace Tech
1,290 Listeners
WSJ Your Money Briefing
1,713 Listeners
WSJ What’s News
4,420 Listeners
Bloomberg Intelligence
406 Listeners
HBR IdeaCast
154 Listeners
How to Be Awesome at Your Job
1,036 Listeners
GZERO World with Ian Bremmer
837 Listeners
The Readout Loud
337 Listeners
Thoughts on the Market
1,320 Listeners
The Journal.
6,097 Listeners
The Next Big Idea
1,281 Listeners
BioCentury This Week
34 Listeners
Coaching Real Leaders
678 Listeners
Biotech Hangout
21 Listeners
HBR On Leadership
170 Listeners